d.EVOQUE

The EVOQUE valve (Edwards Lifesciences, Irvine, CA) was recently evaluated in 25 symptomatic (96% NYHA III or IV) patients with severe TR. At 30 days 76% of the patients were in NYHA I/II and 96% had a TR 2+ with a 92% of technical success [57].
